Q901 + pembrolizumab

Q901 + pembrolizumab is a combination investigational therapy consisting of Q901, a highly selective cyclin dependent kinase 7 (CDK7) inhibitor, and pembrolizumab (marketed as KEYTRUDA), an anti-PD-1 monoclonal antibody immunotherapy. Q901 functions by inhibiting CDK7, a master regulator of cell cycle checkpoints and transcription machinery, resulting in cell cycle arrest, suppression of DNA damage repair pathways, and induction of genomic instability in cancer cells. This can sensitize tumors to immunotherapy, especially those that are resistant, and may also overcome resistance to other therapies like ADCs (antibody-drug conjugates). Pembrolizumab blocks the PD-1/PD-L1 pathway, thereby activating immune responses against cancer cells. The combination is being clinically evaluated, particularly in patients with advanced solid tumors who have limited treatment options. Q901 is developed by Qurient, which licensed the CDK7 program from Lead Discovery Center (LDC) and the Max Planck Society. The combination therapy is being tested under a clinical collaboration agreement between Qurient and MSD (Merck & Co.)[2][3][8].

Brand names

KEYTRUDA

Other names

Q901 + KEYTRUDAQ901 + pembrolizumab